肺部给药用高分子多孔微球的制备及改性研究进展

肺部给药作为一种非入侵式的给药方式,在蛋白质、多肽类药物的给药研究中具有很大的发展潜力。高分子多孔微球是最适合肺部给药的药物载体之一,本文首先阐述了高分子多孔微球的几种传统制备方法,分析了这些制备方法在不同的条件下存在的优点及缺点。随后本文针对传统的高分子多孔微球制备条件难以单独控制,药物不能有效包封等问题,对近年来研究者们为了提高多孔微球的性能对其进行的物理化学改性进行了综述并提出了观点。最后对肺部给药用高分子多孔微球不同的制备方法的相互结合以及在生物医学领域的应用价值进行了展望。     

靶向性药物载体-磁性淀粉微球的制备及性质

采用乳化复合技术制备出粒径为（50－375）mm、分散系数为0．2736、Fe3O4质量分数为38％的具有磁核的淀粉复合微球。微球呈蛛形,表面光滑,在水中可形成稳定的分散液,在0．05T弱磁场中具有强磁响应性。制备微球的最佳条件是：淀粉用量为（95．7－178．5）g/l,氯化亚铁用量为（17．79－88．96）g/l,pH＞9．7。     

磁性高分子微球固定化酶的制备及应用

利用磁性高分子微球通过化学反应固定化酶,可以借助外部磁场方便地分离回收固定化酶,将固定化酶放入磁场稳定的流动床反应器中还可以减少持续反应体系中的操作.简要地介绍了磁微球的制备方法,包括包埋法、分散聚合、乳液聚合和悬浮聚合,对磁性微球固定化酶的制备方法和原理进行了探讨,论述了磁性高分子微球固定化酶的特点及应用.     

口服结肠靶向给药系统和制备方法的研究进展

口服结肠靶向给药系统作为第四代药物剂型的发展和应用,具有靶向定位性、可提高局部药物浓度、直接作用于病变部位、降低药物剂量、减少副反应等优点,因而备受研究者的关注。本文针对口服结肠靶向给药系统的给药机理、应用和制备技术,综述了该领域近些年来的研究进展,为系统研究口服结肠靶向给药系统提供理论依据和参考。     

药物载体磁性高分子微球的制备及应用研究进展

介绍了药物载体磁性高分子微球的研究现状,总结了常用的制备方法及应用进展,展望了磁性高分子微球的发展前景。     

磁性生物高分子微球的研究

生物高分子磁性微球是一种新型功能材料,在化工、生物工程、生物医学等许多方面有良好的应用前景。对磁性高分子微球的研究进展进行了综述,介绍了各类微球的制备方法及相关原理,并对磁性高分子微球的未来研究方向进行了展望。在此基础上,概述了生物高分子磁性微球的结构、性质及在固定化酶、靶向药物、细胞分离与免疫分析等领域的应用。     

半乳糖介导的主动肝靶向给药系统研究进展

肝脏疾病严重危害人类健康,目前仍以药物治疗为主。传统药物剂型组织选择性低,给药后只有少量药物分子能分布于肝脏病变区产生治疗作用,限制了药物本身的治疗效果。主动靶向给药系统能将药物递送至特定的肝脏病变区,提高药物在肝组织的分布,增强药物的治疗效果,同时减小对正常组织的毒副作用。其中半乳糖介导的主动靶向给药系统能够通过识别肝实质细胞及肝癌细胞膜表面过表达的ASGP-R实现药物的肝靶向递送,是目前最有应用前景的主动肝靶向方式之一,本文结合近几年相关文献报道,对半乳糖介导的主动肝靶向给药系的研究进展进行综述。     

磁性微球的生物医学应用研究进展

磁性微球作为一种新型功能材料 ,在生物医学、细胞学和生物工程学等领域被广泛地应用于生物目标产品的快速分离 ;在临床医学方面被广泛应用于靶向给药。对磁性微球在生物分离和靶向药物等领域的应用进行了详细的介绍     

磁性高分子微球的制备

磁性微球是一种新型功能材料,具有磁效应和小尺寸效应,在众多领域展现出巨大的应用潜力。本文综述了磁性微球的制备方法,磁性高分子微球目前有三种主要的的制备方法:包埋法、原位沉积法、单体聚合法。单体聚合法又以悬浮聚合法、乳液聚合法、分散聚合法为主。     

磁性高分子微球的制备及其应用

介绍了有机高分子与磁性氧化铁复合的制备方法,总结了磁性高分子微球在废水处理、生物工程方面的应用,并对其发展趋势做了展望。     

药库型微型胶囊囊材研究进展

微包囊、微球作为一种新的药物释放体系,具有极大的发展潜力.药物载体是药物释放体系的重要组成部分,也是影响药效的主要因素.磁性微球、纳米胶囊的出现对囊材与载体材料的研究提出了新的要求.对药库型微型胶囊囊材与载体材料的研究现状与发展趋势进行了综述.     

生物粘附性微球的制备及其评价-I. 离子交联法制备生物粘附性微球及其粒径预测

以硫酸为离子交联剂,制备了几丁聚糖生物粘附性微球. 与硫酸盐作为离子交联剂相比,本方法制备的微球交联程度高,呈较规则的球形,表面致密,机械强度高,在人工模拟肠液中可以保存24 h以上. 微球的粒径是影响药物释放动力学的重要因素. 运用四因素二次正交回归组合设计方法考察了几丁聚糖浓度、交联剂浓度、交联时间和转速对微球粒径的影响,得出了制备几丁聚糖微球粒径的回归模型方程. 统计检验表明,其中几丁聚糖浓度和搅拌转速对微球粒径的影响最为显著.     

聚乳酸载药系统的研究进展

聚乳酸及其共聚物由于其生物相容性和生物可降解性,被广泛应用于医药和生物学领域。文章就国内外对聚乳酸及其共聚物作为新型载药系统的研究,进行了归纳总结。旨在说明聚乳酸作为药物载体的优势和发展前景。     

纳米羟基磷灰石在药物载体中的应用

综述了纳米羟基磷灰石(HAP)作为药物或基因载体的研究现状及其生物相容性评价,指出了HAP纳米粒子作为药物或基因载体的主要发展趋势及存在的问题。药物或基因载体的研究较多,但是尚未找到一种理想的载体材料。作为一种新的药物基因载体,HAP纳米粒子有高的药物吸附量及良好的生物相容性,有望作为一种新的基因药物载体。     

壳聚糖-琼胶复合微球的制备及其药物释放性能

采用小分子离子交联法制备了pH值敏感的壳聚糖-琼胶复合微球,对壳聚糖-琼胶复合微球的粒径、形貌、pH值敏感性等进行了表征.以茶碱为模型药物研究了壳聚糖-琼胶复合微球的药物释放性能,结果发现一定量琼胶的引入有助于改善壳聚糖微球的药物缓释性能.     

Current Advances in Specialised Niosomal Drug Delivery: Manufacture,Characterization and Drug Delivery Applications

Development of nanomaterials for drug delivery has received considerable attention due to their potential for achieving on-target delivery to the diseased area while the surrounding healthy tissue is spared. Safe and efficiently delivered payloads have always been a challenge in pharmaceutics. Niosomes are self-assembled vesicular nanocarriers formed by hydration of a non-ionic surfactant, cholesterol or other molecules that combine to form a versatile drug delivery system with a variety of applications ranging from topical delivery to targeted delivery. Niosomes have advantages similar to those of liposomes with regards to their ability to incorporate both hydrophilic and hydrophobic payloads. Moreover, niosomes have simple manufacturing methods, low production cost and exhibit extended stability, consequently overcoming the major drawbacks associated with liposomes. This review provides a comprehensive summary of niosomal research to date, including the types of niosomes and critical material attributes (CMA) and critical process parameters (CPP) of niosomes and their effects on the critical quality attributes (CQA) of the technology. Furthermore, physical characterisation techniques of niosomes are provided. The review then highlights recent applications of specialised niosomes in drug delivery. Finally, limitations and prospects for this technology are discussed.     

离子交换材料在药物传递系统的应用

离子交换材料作为一种新型的药用高分子材料近年来在药剂学中的应用广泛,在药物传递系统中的应用研究迅速。但离子交换技术及离子交换材料在药剂学中的应用仍存在许多不足。归纳了离子交换材料的种类、特性,以及离子交换材料作为药物载体在药物制剂方面的应用。提出了研制功能性离子交换树脂辅料将是未来发展方向。     

含糖聚合物在药物释放应用中的新进展

含糖聚合物因其优良的亲水性和生物相容性成为近期研究的热点,并且被广泛应用于生物医药领域。综述了含糖聚合物作为药物缓释载体应用的新进展。     

Transdermal Drug Delivery Systems and Their Use in Obesity Treatment

Transdermal drug delivery (TDD) has recently emerged as an effective alternative to oral and injection administration because of its less invasiveness, low rejection rate, and excellent ease of administration. TDD has made an important contribution to medical practice such as diabetes, hemorrhoids, arthritis, migraine, and schizophrenia treatment, but has yet to fully achieve its potential in the treatment of obesity. Obesity has reached epidemic proportions globally and posed a significant threat to human health. Various approaches, including oral and injection administration have widely been used in clinical setting for obesity treatment. However, these traditional options remain ineffective and inconvenient, and carry risks of adverse effects. Therefore, alternative and advanced drug delivery strategies with higher efficacy and less toxicity such as TDD are urgently required for obesity treatment. This review summarizes current TDD technology, and the main anti-obesity drug delivery system. This review also provides insights into various anti-obesity drugs under study with a focus on the recent developments of TDD system for enhanced anti-obesity drug delivery. Although most of presented studies stay in animal stage, the application of TDD in anti-obesity drugs would have a significant impact on bringing safe and effective therapies to obese patients in the future.     

Preparation and in Vivo Evaluation of a Dutasteride-Loaded Solid-Supersaturatable Self-Microemulsifying Drug Delivery System

The purpose of this study was to prepare a dutasteride-loaded solid-supersaturatable self-microemulsifying drug delivery system (SMEDDS) using hydrophilic additives with high oral bioavailability, and to determine if there was a correlation between the in vitro dissolution data and the in vivo pharmacokinetic parameters of this delivery system in rats. A dutasteride-loaded solid-supersaturatable SMEDDS was generated by adsorption of liquid SMEDDS onto Aerosil 200 colloidal silica using a spray drying process. The dissolution and oral absorption of dutasteride from solid SMEDDS significantly increased after the addition of hydroxypropylmethyl cellulose (HPMC) or Soluplus. Solid SMEDDS/Aerosil 200/Soluplus microparticles had higher oral bioavailability with 6.8- and 5.0-fold higher peak plasma concentration (C_max) and area under the concentration-time curve (AUC) values, respectively, than that of the equivalent physical mixture. A linear correlation between in vitro dissolution efficiency and in vivo pharmacokinetic parameters was demonstrated for both AUC and C_max values. Therefore, the preparation of a solid-supersaturatable SMEDDS with HPMC or Soluplus could be a promising formulation strategy to develop novel solid dosage forms of dutasteride.